The invention provides a crystal form of an icaritin compound, a drug containing the crystal form and an application of the crystal form. The crystal form is a solvent-free crystal form, and the X-ray powder diffraction measured by using Cu-Ka rays has peak values at the angles 2theta which are respectively 6.0+/-0.2 DEG, 11.4+/-0.2 DEG, 13.0+/-0.2 DEG and 18.9+/-0.2 DEG. The invention also provides an application of the crystal form to preparation of a drug for treating diseases related to abnormal cell proliferation. The crystal form provided by the invention is high in stability, free of risks for converting into other crystal forms and suitable for transportation and storage in extreme weather.
